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ORIGINAL ARTICLE
Cadmium (Cd) is a metallic toxin of major envi-
ronmental and occupational concern. It is a sus-
pected human prostatic carcinogen and has been
shown to induce prostatic tumors and prolifera-
tive lesions in rats.1,2 Some studies have indicated
that tissue levels of Cd in the human prostate
correlate with malignant disease.3 Therefore, Cd
has a possible role as an etiological agent in human
prostate cancer (CaP).1–4 Cd, like other metal-
lothionein (MT)-bound metals, is very toxic in a
variety of tissues.5
MT is a low-molecular-weight protein that is
rich in cysteine and is a heavy-metal-binding pro-
tein. MT is rich in thionein moieties, which play
a role in detoxification of metals such as Cd and
Hg, in homeostasis of essential metals such as
Zn and Cu, and in the protection of cells against
damage induced by alkylating agents, oxygen
radicals, and ionizing radiation.6–11
In the present study, we investigated Cd con-
centration and MT expression in patients with
benign prostatic hyperplasia (BPH) or CaP. 
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Our goal was to clarify the relationship between
Cd concentration and MT expression in prostatic
diseases.
Material and Methods
Patients
We enrolled 53 patients between 1 January 2005
and 30 June 2007. Their ages ranged from 65 to
75 years. None were smokers. The experimental
group included 18 patients who had radical
prostatectomy for primary CaP. Specimens were
obtained from resected tumor tissue (the tumor
area was defined by our pathologist). The control
group consisted of 35 patients who had a prostate-
specific antigen level < 4 ng/mL, who underwent
transurethral resection of the prostate for BPH
(determined by the same pathologist). All pro-
static tissues were resected and some stored at 
− 80°C until Cd measurement and MT determi-
nation with atomic absorption spectrophotome-
try and western blotting, respectively. The other
tissues were fixed with formalin and embedded
in paraffin blocks for subsequent immunohisto-
chemical staining. All specimens were removed
only after obtaining informed written consent
from the patients.
Measurement of Cd
Cd was measured in tissue specimens using a mod-
ification of our previously described method.12
Fifty-three prostatic specimens were washed three
times in tap water and briefly rinsed in double-
deionized water within 1 minute to remove blood
contaminants and ions from the tissue surface;
water left on the prostate surface was blotted 
dry with filter paper. Prostatic tissues were dried
at 65°C overnight in order to nitrate tissues 
completely—then each was nitrated overnight
with 200 μL of 13.1 N HNO3 at 40°C. The di-
gested solutions, as well as aqueous samples
from the incubation media, were diluted with
double-deionized water and subjected to atomic
absorption spectrophotometry (Z-8000; Hitachi,
Japan), using a graphite furnace for Cd analysis
according to standard methods modified from
Chang et al.13 Cd standard solutions (Merck,
Germany) were used for establishing standard
curves. The standard addition method was used
for background correction to eliminate the matrix
effect.
MT immunoblotting
MT extraction and immunoblotting were carried
out as described in our previous study.14 Prostatic
tissues were prepared by homogenization in
10 mM Tris–HCl with 5 mM 2-mercaptoethanol,
pH 7.0. The homogenate was centrifuged at
12,000g for 40 minutes at 4°C. The supernatant
was inactivated at 80°C for 10 minutes, and was
centrifuged again at 12,000g for 40 minutes at
4°C. The final supernatants were subjected to
MT western blotting as described below.
Samples (20 μg) of total prostate protein were
loaded in triplicate and subjected to polyacryl-
amide gel electrophoresis on 15% polyacryl-
amide gels for 1 hour at 125 V. The separated
proteins were transferred to polyvinylidene diflu-
oride membranes (Millipore, Billerica, MA, USA)
by electroblotting. After preincubation for 2 hours
in PBST buffer, which contained 1–2% (w/v)
nonfat dried milk to minimize nonspecific bind-
ing, the blots were trimmed into two pieces. One
of the two pieces was incubated for 1 hour in pri-
mary anti-MT antibody (rabbit monoclonal anti-
body; United States Biological, Swampscott, MA,
USA) and diluted in 5% BSA (1:8000). The other
piece was incubated with β-actin antibody (Sigma,
St Louis, MO, USA) as a positive control. Both
were washed in PBST and allowed to react for 2
hours with alkaline-phosphatase-conjugated sec-
ondary antibody (KPL, Gaithersburg, MD, USA;
1:4000). Blots were developed after incubation
with 0.015% nitro-blue tetrazolium and 0.007%
bromochloroindolyl phosphate in a reaction
buffer that contained 100 mM Tris, 100 mM NaCl
and 5 mM MgCl2 (pH 9.5). Immunoblots were
scanned and imported as JPG files into a commer-
cial software package (Photo-Capt; Vilber Lourmat,
Marne-la-Vallée, France). The results were con-
verted to numerical values and a ratio of MT to 
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β-actin was calculated using the same lane, in
order to compare the relative intensities of the
immunoreactive bands.
Immunohistochemistry for MT
Sections were dewaxed with xylene and ethanol,
and rinsed in phosphate buffered saline (PBS).
Endogenous peroxidase was inactivated by incu-
bating the sections with 3% H2O2. Sections were
stained immunohistochemically with rabbit poly-
clonal antibody IgG (sc-11377; Santa Cruz Bio-
technology, Santa Cruz, CA, USA; dilution 1:200)
for all MT isoforms, followed by analysis for MT
using a commercial kit (PicTure; Zymed, South
San Francisco, CA, USA). The negative control was
PBS instead of primary antibody. Finally, sections
were counterstained with hematoxylin (Merck)
and rinsed with tap water. Sections were observed
using a light microscope (Olympus BX50; Tokyo,
Japan) and micrographs were taken with a digi-
tal camera (Nikon Coolpix 5000; Tokyo, Japan).
Statistical analysis
Data were analyzed with Student’s t tests; p < 0.05
was considered statistically significant.
Results
MT immunoblots from both groups revealed a
single band (Figure 1). There were no significant
differences in Cd concentration between the
BPH (1.11 ± 0.08 μg/kg) and CaP (1.09 ± 0.12
μg/kg) groups (Figure 2). However, the relative
intensity of the MT band was 0.58 ± 0.09 in the
BPH group and 0.17 ± 0.03 in the CaP group.
Hence, MT expression in BPH patients was about
3.4-fold higher than in patients with CaP (Figure
2). Immunohistochemical staining for MT showed
stronger immunoreactivity in the cytoplasm of
prostatic epithelium in the BPH group (Figures
3A and 3B) than in the CaP group (Figures 3C
and 3D).
Discussion
Cd is a toxic metal and has been reported to in-
crease the risk of CaP.1,2 The pathogenesis of Cd
MT (54 kDa)
BPH CaP
β-actin (42 kDa)
Figure 1. Representative immunoblots and relative intensity of metallothionein protein in human prostate cancer and
benign prostatic hyperplasia groups. β-actin was used as a loading control.
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Figure 2. Mean metallothionein protein (MT) levels in the
benign prostatic hyperplasia (BPH) group were 3.4-fold
higher than in the human prostate cancer (CaP) group.
However, there was no significant difference in cadmium
(Cd) concentrations.
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prostatic carcinogenesis might include aberrant
gene expression that results in stimulation of cell
proliferation or inhibition of apoptosis.4 How-
ever, the Cd–MT complex formed is nontoxic. It
has been proposed that MT is a chelator that
binds to harmful heavy metals and excessive
amounts of essential metals.15 In the present
study, MT expression in the BPH group was 3.4-
fold higher than the CaP group. We suggest that
the greater level of Cd–MT complexes and lower
level of free Cd2+ in BPH patients lead to less Cd-
induced cell toxicity and carcinogenesis than the
CaP group. Previous studies have reported that
adenoma appears to contain a higher Cd content
than normal prostate.16 Ogunlewe and Osegbe17
have also reported that Cd concentrations are
higher in CaP patients compared with normal
prostates or BPH patients. However, these studies
have not researched the relationship between CaP,
Cd concentration, and MT expression in the same
specimens. In addition, they have focused only
on total Cd content and ignored free Cd level.
MT is a low-molecular-weight, cysteine-rich
protein. It is inducible during acute stress and is
a free radical scavenger that protects cells from
oxidative damage during inflammation.18 The
antioxidant properties of MT may participate in-
dependently or in conjunction with glutathione
to protect cells against injurious agents and stress
stimuli.19 Each of these responses and intermedi-
ates, including metals, glucocorticoids and cy-
tokines, are able to induce MT protein synthesis.18
A B
C D
Figure 3. Metallothionein immunohistochemical staining pattern in prostatic sections from the benign prostatic hyper-
plasia groups (A and B) and human prostate cancer groups (C and D). (A) Photomicrograph of a representative prostatic
section after hematoxylin staining. This is a negative control (400×). (B) Intense immunohistochemical staining for met-
allothionein, particularly in the cytoplasm (arrow) of prostatic epithelium (400×). (C) Photomicrograph of a representa-
tive human prostate cancer section after hematoxylin staining. This is a negative control (400×). (D) Weak
immunohistochemical staining of prostatic epithelium (arrow) for metallothionein (400×).
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Recent studies have demonstrated that MT mRNA
and protein are correlated highly with Cd levels
at low doses, but MT expression is reduced at
high doses.15 These results imply that the dose
response for MT expression is relevant only when
heavy metals do not exert detrimental effects on
physiological functions.15,20 The present study
showed that MT synthesis was lower in the CaP
than the BPH group, but there was no statisti-
cally significant difference in total Cd concentra-
tion (free + bound). Combining the previous and
present data, there are two possibilities: (1) can-
cer cells cannot carry out normal MT synthesis;
and (2) MT chelates more Cd in patients with
BPH compared with CaP. However, both candi-
date hypotheses need to be confirmed in future
studies.
A number of studies have shown an increase
in MT expression in human tumors of the breast,
colon, kidney, lung, nasopharynx, ovary, thyroid,
and urinary bladder.21,22 However, MT is down-
regulated in other tumors such as hepatocellular
carcinoma and liver adenocarcinoma.20 Hence,
the expression of MT is not universal to all human
tumors, but may depend on their differentiation
status and proliferative index.21 Most previous
studies have ignored a number of factors in their
analysis, including stimulators such as free radi-
cals, smoking, foods, toxic heavy metals, and
some genes—all of these can interfere with MT
synthesis.23–28
To the authors’ knowledge, this is the first
study to analyze the relationship between Cd con-
tent and MT expression in prostatic diseases simul-
taneously. Previous studies have not researched
the relationship between prostate tissues, Cd con-
centration and MT expression in the same speci-
mens. Our results showed that the BPH group
had greater MT expression than the CaP group,
but the Cd concentration did not appear to differ
significantly between the groups. We suggest that
MT may have protective effects against CaP.
However, additional studies are needed to reveal
the factors that influence the expression of MT in
prostate epithelial cells and to analyze the free
and compound forms of Cd at the same time.
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